BACKGROUND: There are few published data describing the mortality burden associated with influenza and respiratory syncytial virus (RSV) infection in children in low- and middle-income countries and particularly from Africa and settings with high prevalence of human immunodeficiency virus (HIV). METHODS: We modeled the excess mortality attributable to influenza (seasonal and pandemic) and RSV infection by applying Poisson regression models to monthly all-respiratory and pneumonia and influenza deaths, using national influenza and RSV laboratory surveillance data as covariates. In addition, we estimated the seasonal influenza- and RSV-associated deaths among HIV-infected and -uninfected children using Poisson regression models that incorporated HIV prevalence and highly active antiretroviral therapy coverage as covariates. RESULTS: In children <5 years of age, the mean annual numbers of seasonal influenza- and RSV-associated all-respiratory deaths were 452 (8 per 100 000 person-years [PY]) and 546 (10 per 100 000 PY), respectively. Infants <1 year of age experienced higher mortality rates compared with children 1-4 years of age for both influenza (22 vs 5 per 100 000 PY) and RSV (35 vs 4 per 100 000 PY). HIV-infected compared with HIV-uninfected children <5 years of age were at increased risk of death associated with influenza (age-adjusted relative risk [aRR], 11.5; 95% confidence interval [CI], 9.6-12.6) and RSV (aRR, 8.1; 95% CI, 6.9-9.3) infection. In 2009, we estimated 549 (11 per 100 000 PY) all-respiratory influenza A(H1N1)pdm09-associated deaths among children aged <5 years. CONCLUSIONS: Our findings support increased research efforts to guide and prioritize interventions such as influenza vaccination and HIV prevention in low- and middle-income countries with high HIV prevalence such as South Africa.
BACKGROUND: There are few published data describing the mortality burden associated with influenza and respiratory syncytial virus (RSV) infection in children in low- and middle-income countries and particularly from Africa and settings with high prevalence of human immunodeficiency virus (HIV). METHODS: We modeled the excess mortality attributable to influenza (seasonal and pandemic) and RSV infection by applying Poisson regression models to monthly all-respiratory and pneumonia and influenza deaths, using national influenza and RSV laboratory surveillance data as covariates. In addition, we estimated the seasonal influenza- and RSV-associated deaths among HIV-infected and -uninfected children using Poisson regression models that incorporated HIV prevalence and highly active antiretroviral therapy coverage as covariates. RESULTS: In children <5 years of age, the mean annual numbers of seasonal influenza- and RSV-associated all-respiratory deaths were 452 (8 per 100 000 person-years [PY]) and 546 (10 per 100 000 PY), respectively. Infants <1 year of age experienced higher mortality rates compared with children 1-4 years of age for both influenza (22 vs 5 per 100 000 PY) and RSV (35 vs 4 per 100 000 PY). HIV-infected compared with HIV-uninfected children <5 years of age were at increased risk of death associated with influenza (age-adjusted relative risk [aRR], 11.5; 95% confidence interval [CI], 9.6-12.6) and RSV (aRR, 8.1; 95% CI, 6.9-9.3) infection. In 2009, we estimated 549 (11 per 100 000 PY) all-respiratory influenza A(H1N1)pdm09-associated deaths among children aged <5 years. CONCLUSIONS: Our findings support increased research efforts to guide and prioritize interventions such as influenza vaccination and HIV prevention in low- and middle-income countries with high HIV prevalence such as South Africa.
Entities:
Keywords:
HIV; South Africa; influenza; mortality; respiratory syncytial virus
Authors: Igor Rudan; Cynthia Boschi-Pinto; Zrinka Biloglav; Kim Mulholland; Harry Campbell Journal: Bull World Health Organ Date: 2008-05 Impact factor: 9.408
Authors: Maurice O Ope; Mark A Katz; Barrack Aura; Stella Gikunju; M Kariuki Njenga; Zipporah Ng'ang'a; John Vulule; Robert F Breiman; Daniel R Feikin Journal: PLoS One Date: 2011-05-26 Impact factor: 3.240
Authors: Cees C van den Wijngaard; Liselotte van Asten; Marion P G Koopmans; Wilfrid van Pelt; Nico J D Nagelkerke; Cornelia C H Wielders; Alies van Lier; Wim van der Hoek; Adam Meijer; Gé A Donker; Frederika Dijkstra; Carel Harmsen; Marianne A B van der Sande; Mirjam Kretzschmar Journal: PLoS One Date: 2012-02-03 Impact factor: 3.240
Authors: Lone Simonsen; Peter Spreeuwenberg; Roger Lustig; Robert J Taylor; Douglas M Fleming; Madelon Kroneman; Maria D Van Kerkhove; Anthony W Mounts; W John Paget Journal: PLoS Med Date: 2013-11-26 Impact factor: 11.069
Authors: Li Li; Jessica Y Wong; Peng Wu; Helen S Bond; Eric H Y Lau; Sheena G Sullivan; Benjamin J Cowling Journal: Am J Epidemiol Date: 2018-02-01 Impact factor: 4.897
Authors: Johan J Dempers; Jean Coldrey; Elsie H Burger; Vonita Thompson; Shabbir A Wadee; Hein J Odendaal; Mary Ann Sens; Brad B Randall; Rebecca D Folkerth; Hannah C Kinney Journal: J Forensic Sci Date: 2016-09-27 Impact factor: 1.832
Authors: Matthew Biggerstaff; Cheryl Cohen; Carrie Reed; Stefano Tempia; Meredith L McMorrow; Sibongile Walaza; Jocelyn Moyes; Florette K Treurnicht; Adam L Cohen; Paul Hutchinson; Charles Stoecker; Joni Steinberg Journal: Vaccine Date: 2019-09-28 Impact factor: 3.641